Jefferson Site-based Clinical Research Group
Infectious Disease
ICON
Principal Investigator: Joseph A. DeSimone, MD
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
VERTEX
Principal Investigator: Kathleen Squires, MD
An Open-Label Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1 (HCV/HIV–1)
